抄録
<jats:p>Twenty‐five transfusion‐dependent myelodysplastic syndrome (MDS) patients (with < 20% blasts) were treated in a phase II study with antithymocyte globulin (ATG) at 40 mg/kg/d for four doses and then followed with blood counts every 2 weeks and clinic visits every 3 months, for a median of 14 months (range 1–38 months). 11 (44%) patients responded and became transfusion‐independent after ATG, including three complete responses, six partial responses, and two minimal responses. Responses were observed in 9/14 patients (64%) with refractory anaemia (RA) and 2/6 patients (33%) with refractory anaemia with excess blasts (RAEB). Median response duration was 10 months (range 3–38 months). The Kaplan‐Meier estimate of overall survival was 84% at 38 months, with one early death due to pneumonia and two deaths from disease progression to leukaemia. Side‐effects consisted mainly of mild serum sickness in all patients. A single course of ATG restored haemopoiesis in some patients with MDS and was well tolerated.</jats:p>
収録刊行物
-
- British Journal of Haematology
-
British Journal of Haematology 99 (3), 699-705, 1997-12
Wiley
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1361418521077200256
-
- NII論文ID
- 30014740147
-
- ISSN
- 13652141
- 00071048
-
- データソース種別
-
- Crossref
- CiNii Articles